VA testing GLP-1 medication for alcohol use disorder

The Department of Veterans Affairs has launched a major clinical trial to test whether semaglutide, a GLP-1 medication currently approved for diabetes and weight management, can help veterans struggling with alcohol use disorder. The study, called the Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) trial, will enroll more than 600 veterans at 18 VA medical centers nationwide and represents a significant expansion of research into alternative treatments for substance use disorders.

Alcohol use disorder remains a persistent challenge within the veteran community, often linked to service-connected conditions like PTSD, depression, and chronic pain. The VA currently offers evidence-based treatments including counseling, medication-assisted treatment, and residential programs, but researchers are exploring whether GLP-1 receptor agonists might offer an additional tool by affecting parts of the brain involved in reward pathways. This research builds on earlier findings published in March showing that patients taking GLP-1 medications experienced lower rates of alcohol use disorder and other substance use disorders compared to those taking other diabetes medications.

The trial is open to veterans ages 18 to 80 who have been diagnosed with moderate or severe alcohol use disorder. Participants will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety evaluation period. Researchers will track changes in alcohol consumption, overall health outcomes, and quality of life throughout the study. Recruitment began on July 28, and veterans interested in participating can contact their local VA medical center or search for the trial on ClinicalTrials.gov.

VA Secretary Doug Collins emphasized the department's commitment to exploring new treatment options, stating, "By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery." However, the VA issued an important caution: veterans should not self-medicate or replace their current evidence-based alcohol use disorder treatments with GLP-1 medications without first consulting a healthcare provider. Semaglutide is not currently FDA-approved for treating alcohol use disorder, and larger controlled clinical trials like CRAVE are necessary to determine whether it is safe and effective for this purpose.

For disabled veterans, this trial matters because alcohol use disorder often complicates existing service-connected disabilities and can interfere with treatment adherence, mental health stability, and overall quality of life. Many veterans with PTSD, traumatic brain injury, or chronic pain conditions face heightened risk for developing problematic alcohol use. If this research proves successful, it could eventually provide another option in the VA's treatment toolkit, particularly for veterans who have not responded well to existing therapies or who are seeking alternatives to current medication-assisted treatments.

Veterans dealing with alcohol use disorder should continue working with their VA healthcare providers and utilizing proven treatments while this research is underway. Those interested in participating in the CRAVE trial can reach out to their local VA medical center to discuss eligibility and what participation would involve. Even if you're not eligible or interested in the trial, this is a good time to have an honest conversation with your VA provider about alcohol use and available support services, especially if substance use is affecting your health or your ability to manage service-connected conditions.